Penn Medicine Cancer is dedicated to delivering innovative and compassionate care and providing the latest research advancements in cancer.
Joined May 2013
- Tweets 5,582
- Following 1,285
- Followers 5,844
- Likes 2,251
1,490 Photos and videos
In a small trial, the RAS inhibitor daraxonrasib doubled the survival rate for pancreatic cancer. Robert Vonderheide, MD, DPhil, explained how this drug works and what it tells us about the larger push for new treatments for cancers. #ASCO26 spr.ly/6019B8f8OF
2
3
264
An @FDA advisory committee found the benefits of a Truqap combo for advanced prostate cancer outweighed risks. Committee member Kyle Robinson, MD, said doctors have grown accustomed to cross-specialty collabs to address toxicity concerns. @OncNewsCentral spr.ly/6012B8ZPZA
1
288
Stefan Barta, MD, said there is strong medical and scientific value of including sexual and gender minorities (SGM) in cancer research. "Inclusion of SGM patients in trials is essential to ensure equitable, evidence‑informed cancer care.” @CancerTherAdvsr spr.ly/6015B8ZOnL
1
2
174
The @FDA is permitting some pancreatic cancer patients to receive daraxonrasib. Holly Fernandez Lynch, JD, noted the situation has all the ingredients that “bode in favor of an ethical default for the company to set up one of these programs.” @nytimes spr.ly/6014B8Z3de
1
2
466
On #NationalCancerSurvivorsDay, we celebrate all survivors who continue to meet each day with strength, positivity, and resilience. Your everyday heroism inspires hope. #NCSD2026
3
9
224
More than 16% of patients with advanced pancreatic cancer & BRCA gene mutations remained in remission for >5 years after receiving the PARP inhibitor rucaparib following chemotherapy, per a clinical trial led by Kim Reiss, MD. @BasserBRCA @ASCOPost spr.ly/6012B8DTww
2
6
415
Advancements in both detecting & curing cancer have resulted in a higher percentage of people surviving 5 years or more after diagnosis. However, according to Ezekiel Emanuel, MD, PhD, the cost of treatment can steal the spotlight. @usatoday @KFFhealthnews spr.ly/6019B8DrRP
1
4
176
Penn Medicine Cancer retweeted
Jun 3
New @penncancer research presented at @asco shows women taking GLP-1 medications were ~30% less likely to develop breast cancer. spr.ly/6017B8m2Et
2
6
6
1,096
Penn Medicine Cancer retweeted
Jun 3
Led by Dr. Elizabeth McDonald (@PennRadiology/@PennCancer), the retrospective study of 110k women is also published in @JCO_ASCO. While observational, the findings pave the way for a multisite clinical trial to investigate GLP-1s as a breast cancer prevention tool.
7
14
1,681
Penn Medicine Cancer retweeted
May 22
WATCH 👀: Stefan K. Barta, MD, MS, of @PennCancer discusses mogamulizumab-associated rash in cutaneous T-cell lymphoma.
See the whole video here ➡️: hubs.li/Q04hz3GM0
#lymsm #oncology
3
6
709
Penn Medicine Cancer retweeted
In an update to his presentation from last year, @StephenBagleyMD presented new data from a phase 1 trial that used CAR T cell therapy in glioblastoma patients at #ASCO26.
1
1
3
332
Penn Medicine Cancer retweeted
Radiation Oncology representing at #ASCO26 @ASCOPres Reception. @ASCO @ASTRO_org @NehaVapiwala @PennMedicine @PennRadOnc @ASTRO_Chair
3
16
1,238
Penn Medicine Cancer retweeted
May 31
POP QUIZ‼️ How well do you know @ASCO ⁉️
@TonyMok9 @StephenBagleyMD @PennCancer @CUHKofficial @SPHPnews
#ASCO26 #oncology #cancer #cancercare #lcsm #hematology #btsm #medtwitter #gyncsm #medtwitter
2
4
879
Penn Medicine Cancer retweeted
Proud of @TejaVorugantiMD for leading efforts in #YoungLung Cancer @PennMedicine @PennCancer - he is presenting today on patterns, demographic, biological and tx factors. Including a shout out from EO/AYA Research Group Shoutout!
#ASCO26
5
24
2,195
#ASCO26 isn’t just about networking for our clinicians and scientists. We are dedicated to learning and growing to provide better care for our patients—because they deserve it.
2
3
657
Penn Medicine Cancer retweeted
May 31
As AI becomes more integrated into cancer care, patients are turning online to understand how it impacts diagnosis, treatment, and research. But are those resources meeting patients’ needs? @PennCancer @ASCO @PennMDForum🧵
Read more: pennmedicine.org/news/major-…
1
2
8
1,395
Penn Medicine Cancer retweeted
May 31
Led by senior author Henry Litt, MD & presented by Pearl Subramanian, MD at #ASCO26, the research shows: health systems and cancer centers have an opportunity to create more accessible, patient-friendly resources that are readable, trustworthy, and transparent about safety.
2
2
1,529
That’s a wrap on day 1 of #ASCO26! What a great first day. We’ll see you tomorrow! 👋
4
8
1,319
May 29
💻 Hybrid Event!
👥 @CharuAggarwalMD @BalazsHalmosMD @sooryumyang
🥼 Oncologists, Pathologists, Pulmonologists, NPs, PAs, and Nurses
🧬 Attendees will be better able to integrate novel therapies for HER2-mutated advanced NSCLC into clinical practice.
🔗 mdsc.pe/4cxuHqD
6
505
Penn Medicine Cancer retweeted
May 30
Our team is #PennMedicine proud! We’re always repping our shield at #ASCO26 😉
@PennCancer @ASCO @PennMDForum
4
11
1,084